医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Launching on Kickstarter! GUTS-MAN: Japanese Toe Socks Made to Withstand Anything

2022年02月09日 AM09:30
このエントリーをはてなブックマークに追加


 

NARA, Japan

From the providers of the socks that members of the Japanese Self-Defence Force use on exercises and marches, this amazing pair of socks are extra durable, resistant to wear and tear, while also being odour resistant, sweat-absorbing, and quick drying. Using a special toed design it is also made to help prevent sweat collecting in between the toes, allowing your toes to feel a little bit fresher.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220208005045/en/

A favorite of the Japan Self-Defense Forces (Photo: Business Wire)

A favorite of the Japan Self-Defense Forces (Photo: Business Wire)

The durable tack knitting is one of the secrets behind the durability of the socks, allowing them to withstand 100km long distance training as well as being tested as being 6x the strength of ordinary business socks during an abrasion test.

The GUTS-MAN brand toe socks are designed with particular attention to toe length. Not only the Egyptian type of foot with the long big toe, which is common among Japanese people, but also the Greek type of foot, which has a long pointer toe, and the Polynesian type, which has the same length for all toes, can be fitted more comfortably.

Another key point of these socks is the help it gives when concerning fatigue. Thanks to the compression from the socks, the calves aren’t tired as easily.

The makers at TATSUMI TEXTILE hope to bring a whole new style of sock to the United States and to show off the benefits of toed socks that are extremely tough.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005045/en/

CONTACT

Minako Tatsumi

TATSUMI TEXTILE Co., Ltd. Press

607 Tsuchihashi-cho, Kashihara-shi, Nara, 634-0844 Japan

TEL. +81(0)744-22-5229

FAX. +81(0)744-25-2822

Mail: tatsumi@choku.co.jp

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report